Kim TW - Search Results

1

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.

Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Jung KH, Chang HJ. Kim SY, et al. Among authors: kim tw, kim dy, kim jh. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):201-7. doi: 10.1016/j.ijrobp.2012.03.048. Epub 2012 Jun 5. Int J Radiat Oncol Biol Phys. 2013. PMID: 22672749 Clinical Trial.

2

Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.

Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, Shin SS, Kim JS, Choi EK. Kim JC, et al. Among authors: kim tw, kim js, kim hc, kim jh. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53. doi: 10.1016/j.ijrobp.2005.02.046. Int J Radiat Oncol Biol Phys. 2005. PMID: 15913913 Clinical Trial.

3

Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer.

Yu CS, Kim TW, Kim JH, Choi WS, Kim HC, Chang HM, Ryu MH, Jang SJ, Ahn SD, Lee SW, Shin SS, Choi EK, Kim JC. Yu CS, et al. Among authors: kim tw, kim jc, kim hc, kim jh. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1020-6. doi: 10.1016/j.ijrobp.2006.10.013. Epub 2006 Dec 29. Int J Radiat Oncol Biol Phys. 2007. PMID: 17197127

4

Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.

Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Lee SS, et al. Among authors: kim tw, kim wk. Jpn J Clin Oncol. 2007 Jan;37(1):30-7. doi: 10.1093/jjco/hyl134. Jpn J Clin Oncol. 2007. PMID: 17272321

5

Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK. Sym SJ, et al. Among authors: kim tw. Am J Clin Oncol. 2008 Apr;31(2):151-6. doi: 10.1097/COC.0b013e31815878a2. Am J Clin Oncol. 2008. PMID: 18391599

6

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.

Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh DY, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK. Lee J, et al. Among authors: kim tw. Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. doi: 10.1007/s00280-008-0913-5. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169686 Clinical Trial.

7

lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.

Kim YS, Kim JH, Yoon SM, Choi EK, Ahn SD, Lee SW, Kim JC, Yu CS, Kim HC, Kim TW, Chang HM. Kim YS, et al. Among authors: kim tw, kim jc, kim hc, kim jh. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):796-802. doi: 10.1016/j.ijrobp.2008.08.065. Epub 2009 Mar 14. Int J Radiat Oncol Biol Phys. 2009. PMID: 19289261

8

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS. Sohn BS, et al. Among authors: kim tw, kim jc. Oncology. 2009;77(3-4):224-30. doi: 10.1159/000236046. Epub 2009 Sep 7. Oncology. 2009. PMID: 19738388

9

Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.

Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK. Sym SJ, et al. Among authors: kim bs, kim tw. Ann Surg Oncol. 2010 Apr;17(4):1024-32. doi: 10.1245/s10434-009-0838-1. Epub 2009 Nov 26. Ann Surg Oncol. 2010. PMID: 19941081 Clinical Trial.

10

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK. Kim C, et al. Among authors: kim tw. Invest New Drugs. 2011 Apr;29(2):366-73. doi: 10.1007/s10637-009-9363-0. Epub 2009 Dec 9. Invest New Drugs. 2011. PMID: 19997960 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,593 results

Search Page

Filters